drugset / Trial / NCT03017508

Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder

NCT03017508 ↗

RandomizedCrossoverQuadruple-blindOther

Summary

The goal of the current proposal is to examine if sublingual riluzole can reduce anxiety in people with social anxiety disorder during a public speaking task.

Timeline

Start
2017-01
Primary completion
2019-12
Completion
2021-01-29

Outcome

Missed primary endpoint

registry analysis (superiority test); BHV-0223 (Sublingual Riluzole) vs Placebo; p = 0.056; Mean Difference (Final Values) -8.34; t-test, 2 sided NCT03017508 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Riluzole Small molecule 35 mg Other

Indications